organization · Reporting owner

Simcere Zaiming, Inc.

Disclosed activity across 1 company

Tapewire entity: 24249
SEC CIK: 0002080252

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

No relationships currently tracked through insider filings.

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

No balances currently tracked through insider filings.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

NextCure, Inc.

Report date August 10, 2026 · Filed August 12, 2026

Jointly reported with Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., Simcere Zaiming Pharmaceutical Co., Ltd., Simcere Pharmaceutical Group Ltd, Ren Jinsheng, Tang Renhong

Section 16 reporting ended · disclosed 2026-08-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	308,636	Reported balance After 2026-08-10 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2026-08-10 · Sale · Disposed 30,000 · Balance 308,636 F1: The securities reported herein were directly held by Simcere Zaiming, Inc. ("Simcere Zaiming") and may be deemed to have been indirectly beneficially owned by the other Reporting Persons. F2: Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. ("Jiangsu Zaiming") is the sole shareholder of Simcere Zaiming. Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical Co., Ltd.) is the sole shareholder of Jiangsu Zaiming. Simcere Pharmaceutical Group Limited ("Simcere Group") is the controlling shareholder of Simcere Zaiming Pharmaceutical Co., Ltd. through several intermediate companies. Mr. Jinsheng Ren is the chairman of the board of directors of Simcere Group and a director of Simcere Zaiming Pharmaceutical Co., Ltd. Mr. Renhong Tang is a director of Simcere Group, the chief executive officer and chairman of the board of directors of Simcere Zaiming Pharmaceutical Co., Ltd., a director of Jiangsu Zaiming and the chief executive officer and sole director of Simcere Zaiming. Messrs. Ren and Tang may be deemed to be the beneficial owners having shared voting power and shared investment power over the securities described herein. F3: Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that any Reporting Person is the beneficial owner of any of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The securities reported herein were directly held by Simcere Zaiming, Inc. ("Simcere Zaiming") and may be deemed to have been indirectly beneficially owned by the other Reporting Persons.

F2: Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. ("Jiangsu Zaiming") is the sole shareholder of Simcere Zaiming. Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical Co., Ltd.) is the sole shareholder of Jiangsu Zaiming. Simcere Pharmaceutical Group Limited ("Simcere Group") is the controlling shareholder of Simcere Zaiming Pharmaceutical Co., Ltd. through several intermediate companies. Mr. Jinsheng Ren is the chairman of the board of directors of Simcere Group and a director of Simcere Zaiming Pharmaceutical Co., Ltd. Mr. Renhong Tang is a director of Simcere Group, the chief executive officer and chairman of the board of directors of Simcere Zaiming Pharmaceutical Co., Ltd., a director of Jiangsu Zaiming and the chief executive officer and sole director of Simcere Zaiming. Messrs. Ren and Tang may be deemed to be the beneficial owners having shared voting power and shared investment power over the securities described herein.

F3: Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that any Reporting Person is the beneficial owner of any of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 10, 2026 Filed Aug 12, 2026 15:35 UTC	NextCure, Inc. NXTC · Entity 7461	SaleCommon Stock	30,000	$6.16	$184,800.00	Disclosure SEC source: 0001213900-26-088156 · ownership.xml · nonDerivative · entry 1 Simcere Zaiming, Inc. · CIK 0002080252 · Former 10% Owner Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. · CIK 0002082506 · Former 10% Owner Simcere Zaiming Pharmaceutical Co., Ltd. · CIK 0002088064 · Former 10% Owner Simcere Pharmaceutical Group Ltd · CIK 0002082516 · Former 10% Owner Ren Jinsheng · CIK 0001455397 · Former 10% Owner Tang Renhong · CIK 0002088593 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 308,636 F1 · ownership.nature: The securities reported herein were directly held by Simcere Zaiming, Inc. ("Simcere Zaiming") and may be deemed to have been indirectly beneficially owned by the other Reporting Persons. F2 · ownership.nature: Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. ("Jiangsu Zaiming") is the sole shareholder of Simcere Zaiming. Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical Co., Ltd.) is the sole shareholder of Jiangsu Zaiming. Simcere Pharmaceutical Group Limited ("Simcere Group") is the controlling shareholder of Simcere Zaiming Pharmaceutical Co., Ltd. through several intermediate companies. Mr. Jinsheng Ren is the chairman of the board of directors of Simcere Group and a director of Simcere Zaiming Pharmaceutical Co., Ltd. Mr. Renhong Tang is a director of Simcere Group, the chief executive officer and chairman of the board of directors of Simcere Zaiming Pharmaceutical Co., Ltd., a director of Jiangsu Zaiming and the chief executive officer and sole director of Simcere Zaiming. Messrs. Ren and Tang may be deemed to be the beneficial owners having shared voting power and shared investment power over the securities described herein. F3 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that any Reporting Person is the beneficial owner of any of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.